ARRDC2

Across TCGA pan-cancer cohorts, ARRDC2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ARRDC2 data layer compared with 21 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ARRDC2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ARRDC2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

BLCA, STAD, and COAD are the cancer types where ARRDC2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.212	0.720	.007	12	view →
STAD	OS	Median	III,IV	0.003	0.633	<.001	12	view →
COAD	DFS	Median	All	0.205	0.696	.007	12	view →
SKCM	DFS	Median	II,III,IV	1.000	0.546	.034	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ARRDC2–BLCA (OS)

Open the BLCA breakdown →